David B. Bregman

4.1k citations

43 papers · 3.3k indexed · h-index 28

Impact in

Hematology top 1%
- Iron Metabolism and Disorders
- Erythropoietin and Anemia Treatment
Nephrology top 2%
- Parathyroid Disorders and Treatments

Papers in

Hematology 10
- Iron Metabolism and Disorders 10
- Erythropoietin and Anemia Treatment 9
Genetics 8
- Hemoglobinopathies and Related Disorders 8

Co-authors: Stephen L. Warren Todd A. Koch Lei Du Myles Wolf C S Rubin Sarina van der Zee David L. Morris Lawrence T. Goodnough
Journals: Journal of Biological Chemistry (6 papers)Nephrology Dialysis Transplantation (3 papers)American Heart Journal (2 papers)Proceedings of the National Academy of Sciences (2 papers)The Journal of Cell Biology (2 papers)
Partner nations: United States Netherlands Italy

In The Last Decade

David B. Bregman

43 papers receiving 3.3k citations

Peers

Countries citing papers authored by David B. Bregman

Since Specialization

Citations

This map shows the geographic impact of David B. Bregman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David B. Bregman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David B. Bregman more than expected).

Fields of papers citing papers by David B. Bregman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David B. Bregman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David B. Bregman. The network helps show where David B. Bregman may publish in the future.

Co-authors

The 25 scholars most cited alongside David B. Bregman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David B. Bregman Line = papers co-authored together David B. Bregman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Inhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week Trial Diabetes Care ·Bruce W. Bode, Janet B. McGill, (unknown), C. Pfannenstiel, Pei‐Ching Chang, David B. Bregman, (unknown)	2015	67
2	A multicenter, randomized, active‐controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia Transfusion ·Jane E. Onken, David B. Bregman, Robert A. Harrington, David L. Morris, Péter Ács, Rayane Cunha Vieira, Charles F. Barish, Peng ZhuoMin, David R. Boswell, Angelia Butcher, Todd A. Koch, Lawrence T. Goodnough	2013	125
3	Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial Nephrology Dialysis Transplantation ·Jane E. Onken, David B. Bregman, Robert A. Harrington, David L. Morris, John Buerkert, Татьяна Владимировна Фаненштиль, Iftikhar Hussaın, Roberto Mangoo‐Karim, Edouard Martin, YAO Kai-Lun, George Newman, Wajeh Y. Qunibi, Dennis L. Ross, Bhupinder Singh, Mark T. Smith, Angelia Butcher, Todd A. Koch, Lawrence T. Goodnough	2013	95
4	Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women Journal of Bone and Mineral Research ·Myles Wolf, Todd A. Koch, David B. Bregman	2013	314
5	Intranasal ketorolac tromethamine (SPRIX®) containing 6% of lidocaine (ROX-828) for acute treatment of migraine: Safety and efficacy data from a phase II clinical trial Cephalalgia ·V. Pfaffenrath, WAGEEH ABD. FARRAG, David B. Bregman, Martti Färkkilâ	2012	21
6	Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: A multi-centred, placebo-controlled preliminary clinical trial Sleep Medicine ·Richard P. Allen, Charles H. Adler, Wei Du, Angelia Butcher, David B. Bregman, Christopher J. Earley	2011	112
7	Efficacy of cholesterol uptake inhibition added to statin therapy among subjects following a low-carbohydrate diet: A randomized controlled trial American Heart Journal ·Julio A. Chirinos, Monica Williams, David B. Bregman, Ana Elisa Cabral Savino, Juha Koskela, Nayyar Iqbal	2010	3
8	Randomized Evaluation of efficacy and safety of ferric carboxymaltose in Patients with iron deficiency Anaemia and Impaired Renal function (REPAIR-IDA): rationale and study design Nephrology Dialysis Transplantation ·Félix Fleischer, David B. Bregman, Robert A. Harrington, David L. Morris, Anna Butcher, Thea Koch, Lawrence T. Goodnough, Myles Wolf, Jane E. Onken	2010	10
9	The Inhibitor of Cyclin-Dependent Kinase 4a/Alternative Reading Frame ( *INK4a/ARF* ) Locus Encoded Proteins p16INK4a and p19ARF Repress Cyclin D1 Transcription through Distinct *cis* Elements Cancer Research ·Mark D’Amico, Kongming Wu, Maofu Fu, Mahadev Rao, Chris Albanese, Robert G. Russell, T. Solh�y, David B. Bregman, Michael A. White, Richard G. Pestell	2004	33
10	Oxaliplatin: A Review of Evolving Concepts Cancer Investigation ·Sridhar Mani, Martin A. Graham, David B. Bregman, Percy Ivy, Stephen G. Chaney	2002	55
11	Ultraviolet radiation alters the phosphorylation of RNA polymerase II large subunit and accelerates its proteasome-dependent degradation Mutation Research/DNA Repair ·Zhonghui Luo, Jianhua Zheng, Yi Lu, David B. Bregman	2001	65
12	Hyperphosphorylation of RNA Polymerase II and Reduced Neuronal RNA Levels Precede Neurofibrillary Tangles in Alzheimer Disease Journal of Neuropathology & Experimental Neurology ·Jacob Husseman, Janice L. Hallows, David B. Bregman, James B. Leverenz, David Nochlin, Lee‐Way Jin, Inez Vincent	2001	20
13	The Cockayne syndrome group B DNA repair protein as an anti-cancer target International Journal of Oncology ·Yi Lu, Sridhar Mani, Ekambar R. Kandimalla, Dong Yu, Sudhir Agrawal, J. Christopher States, David B. Bregman	2001	18
14	Limb-girdle Muscular Dystrophy (LGMD-1C) Mutants of Caveolin-3 Undergo Ubiquitination and Proteasomal Degradation Journal of Biological Chemistry ·Ferruccio Galbiati, Daniela Volonté, Carlo Minetti, David B. Bregman, Michael P. Lisanti	2000	80
15	Yeast Carboxyl-terminal Domain Kinase I Positively and Negatively Regulates RNA Polymerase II Carboxyl-terminal Domain Phosphorylation Journal of Biological Chemistry ·Meera Patturajan, Nicholas K. Conrad, David B. Bregman, Jeffry L. Corden	1999	58
16	Ultraviolet Radiation-induced Ubiquitination and Proteasomal Degradation of the Large Subunit of RNA Polymerase II Journal of Biological Chemistry ·E. Reviczky, Bhavani Balasubramanian, Jeffry L. Corden, Stephen L. Warren, David B. Bregman	1998	194
17	Splicing Factors Associate with Hyperphosphorylated RNA Polymerase II in the Absence of Pre-mRNA The Journal of Cell Biology ·Euikyung Kim, Lei Du, David B. Bregman, Stephen L. Warren	1997	206
18	UV-induced ubiquitination of RNA polymerase II: a novel modification deficient in Cockayne syndrome cells. Proceedings of the National Academy of Sciences ·David B. Bregman, Ruth Halaban, Alain J. van Gool, Karla A. Henning, E C Friedberg, Stephen L. Warren	1996	262
19	Cytostellin distributes to nuclear regions enriched with splicing factors Journal of Cell Science ·David B. Bregman, Lei Du, Li Yi, Murray Ballenger, Stephen L. Warren	1994	31
20	Mechanical support of the failing heart and lungs American Heart Journal ·David B. Bregman, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1978	6

About David B. Bregman

David B. Bregman is a scholar working on Hematology, Genetics, Cell Biology, Molecular Biology and Anesthesiology and Pain Medicine, having authored 43 papers that have together received 3.3k indexed citations. Recurring topics across this work include Iron Metabolism and Disorders (10 papers), Erythropoietin and Anemia Treatment (9 papers), RNA Research and Splicing (9 papers), Hemoglobinopathies and Related Disorders (8 papers), DNA Repair Mechanisms (6 papers), RNA and protein synthesis mechanisms (4 papers), RNA modifications and cancer (4 papers) and Genomics and Chromatin Dynamics (3 papers). The work is most often cited by research in Hematology (661 citations), Nephrology (334 citations), Genetics (488 citations), Aging (50 citations) and Molecular Biology (1.9k citations). David B. Bregman has collaborated with scholars based in United States, Netherlands and Italy. Frequent co-authors include Stephen L. Warren, Todd A. Koch, Lei Du, Myles Wolf, C S Rubin, Sarina van der Zee, David L. Morris, Lawrence T. Goodnough, Angelia Butcher and Nitai P. Bhattacharyya. Their work appears in journals such as Journal of Biological Chemistry, Nephrology Dialysis Transplantation, American Heart Journal, Proceedings of the National Academy of Sciences and The Journal of Cell Biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact